1.23
price up icon4.24%   0.05
after-market アフターアワーズ: 1.22 -0.01 -0.81%
loading

Longeveron Inc (LGVN) 最新ニュース

pulisher
Jun 05, 2025

18,190 Shares in Longeveron Inc. (NASDAQ:LGVN) Bought by Northern Trust Corp - Defense World

Jun 05, 2025
pulisher
Jun 02, 2025

Director’s Major Stock Sale Shakes Up Longeveron! - TipRanks

Jun 02, 2025
pulisher
May 29, 2025

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely - Yahoo Finance

May 29, 2025
pulisher
May 22, 2025

Q2 Earnings Estimate for Longeveron Issued By HC Wainwright - Defense World

May 22, 2025
pulisher
May 20, 2025

Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International Convention - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Longeveron® to Attend BIO International Convention 2025 - Yahoo Finance

May 20, 2025
pulisher
May 12, 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

Longeveron Inc. Named Top 40 Semifinalist in XPRIZE Healthspan Competition for Stem Cell Therapy Evaluation in Alzheimer’s Disease and HLHS - Nasdaq

May 12, 2025
pulisher
May 11, 2025

Longeveron (LGVN) Projected to Post Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 09, 2025

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - BioSpace

May 09, 2025
pulisher
May 09, 2025

Longeveron Q1 2025 slides: promising clinical data amid financial headwinds By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Longeveron Reports Q1 2025 Progress and Financials - TipRanks

May 09, 2025
pulisher
May 08, 2025

Earnings call transcript: Longeveron Reports Q1 2025 Results Amid Revenue Decline - Investing.com Canada

May 08, 2025
pulisher
May 07, 2025

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance

May 07, 2025
pulisher
May 03, 2025

Contineum Therapeutics (NASDAQ:CTNM) versus Longeveron (NASDAQ:LGVN) Financial Survey - Defense World

May 03, 2025
pulisher
May 02, 2025

Longeveron Earnings Preview: Latest Updates on Cellular Therapy Pipeline Coming May 8 - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Longeveron Inc. to Report Q1 2025 Financial Results and Business Update on May 8 - Nasdaq

May 02, 2025
pulisher
May 02, 2025

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - The Manila Times

May 02, 2025
pulisher
May 01, 2025

Longeveron Re-approves Cash-to-Equity Program Strategy - TipRanks

May 01, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 22, 2025

Longeveron® Issues Letter to Shareholders Highlighting - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

FDA Green Lights Longeveron's Fast-Track Strategy: Key Trials Near Completion for $10B+ Markets - Stock Titan

Apr 22, 2025
pulisher
Apr 10, 2025

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update - Seeking Alpha

Apr 10, 2025
pulisher
Apr 03, 2025

Where Will Palantir Stock Be in 1 Year? - The Globe and Mail

Apr 03, 2025
pulisher
Mar 28, 2025

Longeveron Files $70 Million Mixed Shelf - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Longeveron Inc Files For Mixed Shelf Of Up To $70 MillionSEC Filing - MarketScreener

Mar 28, 2025
pulisher
Mar 23, 2025

Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Pharma company behind Alzheimer’s treatment closer to FDA approval - The Business Journals

Mar 21, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

FDA aligns with Longeveron on Alzheimer’s therapy trial - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron announces outcome of Type B meeting with FDA on Lomecel-B - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease - The Manila Times

Mar 20, 2025
pulisher
Mar 20, 2025

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

FDA Clears BLA Pathway for Longeveron's Alzheimer's Cell Therapy | LGVN Stock News - Stock Titan

Mar 20, 2025
pulisher
Mar 20, 2025

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire

Mar 20, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication Of Results Of Phase 2A Clinical Trial Evaluating Laromestrocel (Lomecel-B(TM)) In Alzheimer'S Disease - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Laromestrocel shows promise in Alzheimer’s trial - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron announces publication of results of Phase 2a trial of Lomecel-B - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Longeveron Inc. Reports Positive Phase 2a Results for Laromestrocel (Lomecel-B™) in Mild Alzheimer’s Disease Treatment - Nasdaq

Mar 11, 2025
pulisher
Mar 11, 2025

Game-Changing Alzheimer's Treatment: Longeveron's Drug Delivers Cognitive Improvements in Nature Study - StockTitan

Mar 11, 2025
pulisher
Mar 07, 2025

Q1 Earnings Forecast for Longeveron Issued By HC Wainwright - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Q1 Earnings Estimate for Longeveron Issued By Roth Capital - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Q1 Earnings Forecast for Longeveron Issued By Roth Capital - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

FY2025 EPS Estimates for Longeveron Reduced by Analyst - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript - MSN

Mar 06, 2025
pulisher
Mar 05, 2025

Longeveron® to Present at the 37th Annual Roth Conference - The Manila Times

Mar 05, 2025
$1.15
price up icon 0.00%
$585.93
price up icon 0.92%
$300.83
price down icon 2.33%
$38.11
price up icon 4.30%
$4.73
price down icon 1.69%
$493.22
price up icon 2.10%
大文字化:     |  ボリューム (24 時間):